| For: | Rawla P, Sunkara T, Ofosu A, Gaduputi V. Potassium-competitive acid blockers - are they the next generation of proton pump inhibitors? World J Gastrointest Pharmacol Ther 2018; 9(7): 63-68 [PMID: 30595950 DOI: 10.4292/wjgpt.v9.i7.63] |
|---|---|
| URL: | https://www.wjgnet.com/2150-5349/full/v9/i7/63.htm |
| Number | Citing Articles |
| 1 |
AVIJIT MAZUMDER, NAVEEN KUMAR, SAUMYA DAS. A Comprehensive Review of Gastroesophageal Reflux Disease (GERD) Treatment and its Clinical Perspectives. International Journal of Pharmaceutical Sciences and Nanotechnology(IJPSN) 2023; 16(6) doi: 10.37285/ijpsn.2023.16.6.9
|
| 2 |
Chinami Yamawaki, Shunsaku Nakagawa, Keiko Ikuta, Yurie Katsube, Natsuki Imayoshi, Yuki Shigetsura, Daiki Hira, Shinya Yamamoto, Takeshi Matsubara, Motoko Yanagita, Tomohiro Terada. Association between Proton Pump Inhibitors, Immune Checkpoint Inhibitors, and Acute Kidney Injury: A Nested Case–Control Study. Kidney360 2024; 5(9) doi: 10.34067/KID.0000000000000528
|
| 3 |
|
| 4 |
Xianlian Wang, Yongmei Xu, Zaiwei Zong, Jinna Cai, Chunlin Chen, Qingwei Zhang, Xun Sun, Jianqi Li. Design, synthesis and biological evaluation of novel 5-methyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole derivatives as potent potassium-competitive acid blockers. Bioorganic & Medicinal Chemistry 2022; 64 doi: 10.1016/j.bmc.2022.116765
|
| 5 |
Sameh A. Lashen, Mohammed M. Shamseya, Ayman M. Shamseya, Fahmy H. Hablass. Efficacy of Vonoprazan vs. Pantoprazole or Non-acid Suppression in Prevention of Post-variceal Ligation Ulcer Bleeding in Portal Hypertension: A Multi-arm Randomized Controlled Trial. Journal of Clinical and Experimental Hepatology 2023; 13(6) doi: 10.1016/j.jceh.2023.05.008
|
| 6 |
Min Seo Lee, Jihoon Lee, Minyoung Pang, John Kim, Hyunju Cha, Banyoon Cheon, Min-Koo Choi, Im-Sook Song, Hye Suk Lee. In Vitro Metabolism and Transport Characteristics of Zastaprazan. Pharmaceutics 2024; 16(6) doi: 10.3390/pharmaceutics16060799
|
| 7 |
Wen-xin Wang, Rui-jie Li, Xiong-fei Li. Efficacy and Safety of Potassium-Competitive Acid Blockers vs Proton Pump Inhibitors for Peptic Ulcer Disease or Postprocedural Artificial Ulcers: A Systematic Review and Meta-analysis. Clinical and Translational Gastroenterology 2024; 15(9) doi: 10.14309/ctg.0000000000000754
|
| 8 |
Yuchul Jeong, Beom Lee, Se-Hyeon Han. RETRACTED: A Phase III Head-to-Head Study to Compare the Efficacy and Safety of Fexuprazan and Esomeprazole in Treating Patients with Erosive Esophagitis. Journal of Clinical Medicine 2024; 13(11) doi: 10.3390/jcm13113262
|
| 9 |
JaHyun Ho, Bokyoung Kim, Kue Sook Kim, Chang-Ho Jihn, Min-Young Kim, Dae Ryong Kang, You Hyun Park, Jihyun Ahn. Statin Supply and Polydrug Use in Older Adults: A Focus on Drug Combinations that Reduce Bone Density. Annals of Geriatric Medicine and Research 2021; 25(4) doi: 10.4235/agmr.21.0103
|
| 10 |
Vishal Padwale, Vijendra Kirnake, Ravi Daswani, Akshay Kodmalwar, Anusha Gupta. A Comprehensive Review on the Efficacy and Safety of Vonoprazan in the Management of Gastric Acid-Related Diseases. Cureus 2024; doi: 10.7759/cureus.64777
|
| 11 |
Helai Hussaini, Tamiru M Kebede, Tekleweyn S Afework , Deepa Kumari, Olaniyi Fadeyi, Sandipkumar S Chaudhari, Ihtisham Habib, Shamsha Hirani. Comparative Efficacy and Safety of Tegoprazan Versus Proton Pump Inhibitors for Erosive Esophagitis: A Systematic Review and Meta-Analysis. Cureus 2025; doi: 10.7759/cureus.83302
|
| 12 |
Abdelhady S. Ibrahim, Mohammed H.A. Elhaw, Omran M. Mahmoud, Ahmed Q. Mohammed. Vonoprazan-based therapy versus proton-pump inhibitor-based therapy for eradication of Helicobacter pylori: a randomized controlled trial. Al-Azhar Assiut Medical Journal 2026; 24(1) doi: 10.4103/azmj.azmj_83_25
|
| 13 |
Huihui Shang, Huijie Mao, Jiawei Wang, Xiumei Tian, Kaifu Zheng, Jing Wang. Optimizing acid-related disease management: insights into potassium-competitive acid blockers and proton pump inhibitors. European Journal of Clinical Pharmacology 2025; 81(12) doi: 10.1007/s00228-025-03912-9
|
| 14 |
Huiyun Zhu, Qian Xue, Yingxiao Song, Zhenyu Zhang, Xing Li, Shengxiang Lyu, Qiang Zhan, Fei Liu, Lungen Lu, Liang Zhong, Weixing Chen, Dong Shao, Yanbing Ding, Deliang Liu, Xiaozhong Yang, Zhiming Huang, Zhaoshen Li, Yiqi Du. Efficacy and safety of tegoprazan (LXI-15028) vs. esomeprazole in patients with erosive esophagitis: A multicenter, randomized, double-blind, non-inferiority phase Ⅲ trial. Chinese Medical Journal 2025; 138(19) doi: 10.1097/CM9.0000000000003276
|
| 15 |
Yu Kyung Cho, Jae Hak Kim, Hyun‐Soo Kim, Tae‐Oh Kim, Jung‐Hwan Oh, Suck Chei Choi, Jeong Seop Moon, Sang Kil Lee, Sung Woo Jung, Sung Soo Kim, Hye‐Kyung Jung, Sang Pyo Lee, Gab‐Jin Cheon, Moo In Park, Hwoon‐Yong Jung, Kwang Hyun Ko, In Kyung Sung, Si Hyung Lee, Ju Yup Lee, Soo Teik Lee, Poong‐Lyul Rhee, Nayoung Kim, Su Jin Hong, Hyun Jin Kim, Gwang Ha Kim, Kwang Jae Lee, Sung Kook Kim, Woon Geon Shin, Oh Young Lee. Randomised clinical trial: comparison of tegoprazan and lansoprazole as maintenance therapy for healed mild erosive oesophagitis. Alimentary Pharmacology & Therapeutics 2023; 57(1) doi: 10.1111/apt.17255
|
| 16 |
Minyoul Baik, Jeong A. Shin, Joonsang Yoo, Jinkwon Kim, Devesh U Kapoor. Fexuprazan for upper gastrointestinal protection in patients with ischemic stroke and gastroesophageal reflux disease (GERD) receiving antithrombotic therapy: A preliminary prospective single-arm observational Study. PLOS One 2026; 21(4) doi: 10.1371/journal.pone.0346145
|
| 17 |
S. Veni Sri Ambika, S. Gunasekaran, D. Velmurugan, Irena Kostova. Chromatographic fractionation and molecular docking of bioactive component from the leaves of Solanum nigrum for binding affinity with proton pump to inhibit gastric acid secretion. Materials Today: Proceedings 2022; 68 doi: 10.1016/j.matpr.2022.07.427
|
| 18 |
Angela Tietto, Sofia Faggin, Carmelo Scarpignato, Edoardo Vincenzo Savarino, Maria Cecilia Giron. Safety of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease. Expert Opinion on Drug Metabolism & Toxicology 2025; 21(1) doi: 10.1080/17425255.2024.2397433
|
| 19 |
Jeremy Klein, Robert T. Kavitt. Gastroesophageal Reflux Disease. 2023; doi: 10.1007/978-3-031-48241-0_8
|
| 20 |
Kevin Z. Huang, H. Christian Weber. Potassium-competitive acid blockers and acid-related disorders. Current Opinion in Endocrinology, Diabetes & Obesity 2024; 31(3) doi: 10.1097/MED.0000000000000858
|
| 21 |
Sowmya Errabaka, Haritha Pasupulati, Satyanarayana SV Padi. PRAZANs or PCABs, Potassium Competitive Acid Blockers: A New Therapeutic Class in Acid-Related Diseases. International Journal of Health Sciences and Research 2026; doi: 10.52403/ijhsr.20260215
|
| 22 |
Yoo-Seong Jeong, Min-Soo Kim, Nora Lee, Areum Lee, Yoon-Jee Chae, Suk-Jae Chung, Kyeong-Ryoon Lee. Development of Physiologically Based Pharmacokinetic Model for Orally Administered Fexuprazan in Humans. Pharmaceutics 2021; 13(6) doi: 10.3390/pharmaceutics13060813
|
| 23 |
Z. Atwani, A. Hinda, A . Amri, Y. Sebbahi, S. Derraji. Proton Pump Inhibitors and Self-Medication: A Survey Conducted Among Patients in the Casablanca-Settat Region. International Journal of Innovative Science and Research Technology 2025; doi: 10.38124/ijisrt/25mar559
|
| 24 |
Yi Gong, Bo-Wen Yang, Zi-Long Li, Zhong-Rui Liu, Nan-Xing Li, Wei Huang, Tao Chen, Shu-Li Zhao, Jing Chen, Guang-Fu Yang. Distribution- and metabolism-based drug discovery: SAR and SMR exploration of alkoxy-substituted vonoprazan derivatives as new potassium-competitive acid blockers. Bioorganic Chemistry 2026; 169 doi: 10.1016/j.bioorg.2025.109433
|
| 25 |
Lidi Tian, Dan Xiang, Feili Yue, Runjie Li, Youping Zhou. Efficacy and safety of vonoprazan versus proton pump inhibitors in the treatment of peptic ulcer disease: a systematic review and network meta-analysis for randomized controlled trails. Frontiers in Nutrition 2024; 11 doi: 10.3389/fnut.2024.1436993
|
| 26 |
Sufeng Zhou, Lijun Xie, Chen Zhou, Lu Wang, Juan Chen, Sijia Ding, Bei Zhu, Mei Su, Feng Shao. Keverprazan, a novel potassium‐competitive acid blocker: Multiple oral doses safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects. Clinical and Translational Science 2023; 16(10) doi: 10.1111/cts.13598
|
| 27 |
Saba Ahmed, Saad Asghar, Maryam Khanzada, Fnu Soxi, Hamesh Gundala Raja, Mehak Gul, Muhammad M Tariq, Momina Abid, Fazal Carpenter. Comparing Proton Pump Inhibitors and Emerging Acid-Suppressive Therapies in Gastroesophageal Reflux Disease: A Systematic Review. Cureus 2025; doi: 10.7759/cureus.84311
|
| 28 |
Jung Sunwoo, Sang Chun Ji, Jaeseong Oh, Mu Seong Ban, Ji Yeon Nam, Bongtae Kim, Geun Seog Song, Kyung‐Sang Yu, In‐Jin Jang, SeungHwan Lee. Pharmacodynamics of tegoprazan and revaprazan after single and multiple oral doses in healthy subjects. Alimentary Pharmacology & Therapeutics 2020; 52(11-12) doi: 10.1111/apt.16121
|
| 29 |
Ghazal Nabil, Yasmine H. Ahmed, Omaima Ahmed, Selvia S. Milad, Mohamed Hisham, Mohamed Rafat, Mohamed Atia, Aya A. Shokry. Argel's stemmoside C as a novel natural remedy for mice with alcohol-induced gastric ulcer based on its molecular mechanistic pathways. Journal of Ethnopharmacology 2024; 327 doi: 10.1016/j.jep.2024.117970
|
| 30 |
In Mo Yoon, Kang-Yon Kim, Kwan-Haeng Lee, Duk-Woo Yoo, Hojin Oh. Efficacy of Potassium-Competitive Acid Blockers Versus Proton Pump Inhibitors for Gastric Ulcers: Bayesian and Frequentist Network Meta-Analysis With Cross-Inference Through a Quality management System. Current Therapeutic Research 2025; 102 doi: 10.1016/j.curtheres.2025.100776
|
| 31 |
Ji-Hyeon Jeon, Jihoon Lee, Yeon-Ju Baek, Kwon-Jo Lim, Ji Duck Kim, Joon Seok Park, Min-Koo Choi, Im-Sook Song. Restoration of intestinal barrier function by fexuprazan, a potassium-competitive acid blocker, in Caco-2 cells and its higher gastrointestinal distribution in rats. Biomedicine & Pharmacotherapy 2025; 188 doi: 10.1016/j.biopha.2025.118185
|
| 32 |
Scott P. France, Erick A. Lindsey, Emma L. McInturff, Simon Berritt, Andrew C. Flick, Sarah Fink, Tony S. Gibson, Kaitlyn Gray, Aran K. Hubbell, Amber M. Johnson, Yiyang Liu, Subham Mahapatra, Rebecca B. Watson, Zhiyao Zhou. Synthetic Approaches to the New Drugs Approved During 2024. Journal of Medicinal Chemistry 2026; 69(13) doi: 10.1021/acs.jmedchem.6c00287
|
| 33 |
Sufeng Zhou, Lijun Xie, Chen Zhou, Yuqing Zhao, Lu Wang, Sijia Ding, Juan Chen, Bei Zhu, Mei Su, Feng Shao. Keverprazan, a novel potassium-competitive acid blocker: Single ascending dose safety, tolerability, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. European Journal of Pharmaceutical Sciences 2023; 190 doi: 10.1016/j.ejps.2023.106578
|
| 34 |
Chao Liu, Bing Cheng Feng, Yan Zhang, Li Xiang Li, Xiu Li Zuo, Yan Qing Li. The efficacy of vonoprazan for management of post‐endoscopic submucosal dissection ulcers compared with proton pump inhibitors: A meta‐analysis. Journal of Digestive Diseases 2019; 20(10) doi: 10.1111/1751-2980.12813
|
| 35 |
Kyung Sik Park, Hyun-Soo Kim, Jung-Hwan Oh, Woo Chul Chung, Suck Chei Choi, Si Hyung Lee, Tae Ho Kim, Dae Young Cheung, Gwang Ho Baik, Sun Moon Kim, Hang Lak Lee, Jeong Seop Moon, Cheol Woong Choi, Chongil Sohn, Kyoung Oh Kim, Byung-Wook Kim, Hye-Kyung Jung, Da Hyun Jung, Sung Soo Kim, Moo In Park, Ju Yup Lee, Gwang Ha Kim, Hee Seok Moon, Hoonjai Chun, Ki-Nam Shim, Woon Geon Shin, Chan Hyuk Park, Taeoh Kim, Sung Woo Jung, Hyunjin Kim, Sam Ryong Jee, Keemyung Lee, Yu Kyung Cho, Sung Chul Park, Jinwoong Cho, Chealwung Huh, Hyesoo Kwon, Jun Kim, John Kim, Jong-Jae Park. Randomized, Double-Blind, Active-Controlled, Parallel, Phase 3 Clinical Trial for Evaluating the Efficacy and Safety of Zastaprazan in Patients with Gastric Ulcers. Gut and Liver 2026; 20(4) doi: 10.5009/gnl250334
|
| 36 |
Faiz N. Alenezi, Marwa E. Abdelmageed, Manar A. Nader, Marwa S. Zaghloul. Vonoprazan as an adjuvant to cisplatin: enhancing antitumor efficacy while mitigating nephrotoxicity and gastrointestinal adverse effects. Frontiers in Pharmacology 2026; 17 doi: 10.3389/fphar.2026.1798103
|
| 37 |
Inyoung Hwang, Sang Chun Ji, Jaeseong Oh, Hyojin Kim, Hyunju Cha, John Kim, Chang‐Seok Lee, Kyung‐Sang Yu, SeungHwan Lee. Randomised clinical trial: Safety, tolerability, pharmacodynamics and pharmacokinetics of zastaprazan (JP‐1366), a novel potassium‐competitive acid blocker, in healthy subjects. Alimentary Pharmacology & Therapeutics 2023; 57(7) doi: 10.1111/apt.17406
|
| 38 |
Daniel Martin Simadibrata, Ari Fahrial Syam, Yeong Yeh Lee. A comparison of efficacy and safety of potassium‐competitive acid blocker and proton pump inhibitor in gastric acid‐related diseases: A systematic review and meta‐analysis. Journal of Gastroenterology and Hepatology 2022; 37(12) doi: 10.1111/jgh.16017
|
| 39 |
György Miklós Buzás. Dual acid-pump blocking as novel therapeutic approach to treatment of acid-related diseases. Medical Hypotheses 2024; 187 doi: 10.1016/j.mehy.2024.111338
|
| 40 |
Muhammad Miftahussurur, Boby Pratama Putra, Yoshio Yamaoka. The Potential Benefits of Vonoprazan as Helicobacter pylori Infection Therapy. Pharmaceuticals 2020; 13(10) doi: 10.3390/ph13100276
|
| 41 |
György Miklós Buzás, Péter Birinyi. Newer, Older, and Alternative Agents for the Eradication of Helicobacter pylori Infection: A Narrative Review. Antibiotics 2023; 12(6) doi: 10.3390/antibiotics12060946
|
| 42 |
Kanishka Uthansingh, Kenguruka Sidoine, Swarup Kumar Patnaik, Girish Kumar Pati, Rabindra Nath Padhy. Natural Products for Antibacterial Drug Development: Recent Advancement of Computational Approach. 2024; doi: 10.1007/978-981-97-9634-2_8
|
| 43 |
Minyoul Baik, Jimin Jeon, Joonsang Yoo, Jinkwon Kim. Effect of Potassium‐Competitive Acid Blockers on Upper Gastrointestinal Bleeding in Patients on Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Nationwide Cohort Study. Journal of Gastroenterology and Hepatology 2025; 40(7) doi: 10.1111/jgh.16989
|
| 44 |
Siqi Jia, Yuhang Yin, Wenhui Huo, Huiyuan Lu, Yanhong Gao, Xingshun Qi. Proton pump inhibitors for prevention of upper and lower gastrointestinal bleeding in patients taking aspirin: a systematic review and meta-analysis. European Journal of Clinical Pharmacology 2026; 82(8) doi: 10.1007/s00228-026-04135-2
|
| 45 |
Ming Lu, Yi Cui, Nailin Li, Yan He, Ling Zhou, Jin Xiu, Pingsheng Hu. Pharmacological characterization of linaprazan glurate (X842), a novel potassium-competitive acid blocker, in vitro and in vivo. Frontiers in Pharmacology 2025; 16 doi: 10.3389/fphar.2025.1636523
|
| 46 |
Alla Turshudzhyan, Sonia Samuel, Angela Tawfik, Micheal Tadros. Rebuilding trust in proton pump inhibitor therapy. World Journal of Gastroenterology 2022; 28(24): 2667-2679 doi: 10.3748/wjg.v28.i24.2667
|
| 47 |
Sameh A. Lashen, Mohammed M. Shamseyea, Rasha H. Metwally, Galal Abou‐Farrag, Engy S. Elkaragy. Vonoprazan‐Based Triple Therapy Versus Esomeprazole‐Based Triple Therapy for H. pylori Eradication in Adolescents (VONTAPE): A Randomized, Double‐Blind Controlled Trial. Helicobacter 2025; 30(5) doi: 10.1111/hel.70083
|
| 48 |
Kyungwon Yoon, Jung-Tae Kim, Won-Gun Kwack, Donghyun Kim, Kyung-Tae Lee, Seungwon Yang, Sangmin Lee, Yeo-Jin Choi, Eun-Kyoung Chung. Potentially Inappropriate Medication Use in Patients with Dementia. International Journal of Environmental Research and Public Health 2022; 19(18) doi: 10.3390/ijerph191811426
|
| 49 |
Darcy J. Mulford, David A. Gremse, Yu‐Ming Chang, Eckhard Leifke, Thomas Wagner, Axel Facius, Galen Witt. The pharmacokinetics and safety of vonoprazan in adolescents and children with gastroesophageal reflux disease. Journal of Pediatric Gastroenterology and Nutrition 2026; 82(5) doi: 10.1002/jpn3.70368
|
| 50 |
FNU Tanvir, Gurkamal Singh Nijjar, Smriti Kaur Aulakh, Yasmeen Kaur, Sumerjit Singh, Kanwarmandeep Singh, Abhinandan Singla, Ajay Pal Singh Sandhu, Shivansh Luthra, Harman Antaal. Gastroesophageal Reflux Disease: New Insights and Treatment Approaches. Cureus 2024; doi: 10.7759/cureus.67654
|
| 51 |
Sunghwan Kim, Joon Sung Kim. Risk of Depression Related to Use of Proton Pump Inhibitors and Tegoprazan: A Nationwide Cohort Study. Journal of Korean Medical Science 2026; 41(2) doi: 10.3346/jkms.2026.41.e43
|
| 52 |
Xinwei Qiao, Peng Li. Potassium-competitive acid blockers and advances in the management of patients with acid-related diseases: a narrative review. Frontiers in Physiology 2025; 16 doi: 10.3389/fphys.2025.1655102
|
| 53 |
Xiao Li, Cheng Jiang, Yuwen Su, Ruiyun Gao, Peijun Yang, Yuechen Qin, Yue Zou, Weiming Liang, Jieru Quan, Liying Pan. Efficacy and safety of vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for patients with Helicobacter pylori infection: a meta-analysis. Frontiers in Microbiology 2025; 16 doi: 10.3389/fmicb.2025.1561749
|
| 54 |
Taek Kwan Kwon, Jung Hyun Cho, Chun-Woong Park. Novel esomeprazole magnesium bilayer tablet with magnesium hydroxide: enhanced onset time and bioavailability in beagle dogs. Journal of Pharmaceutical Investigation 2025; 55(5) doi: 10.1007/s40005-024-00722-6
|
| 55 |
Min-Gul Kim, Yong-Jin Im, Jong-Hwan Lee, Eun-Young Kim, Sang Woo Yeom, Jong Seung Kim. Comparison of hepatotoxicity of tegoprazan, a novel potassium-competitive acid blocker, with proton pump inhibitors using real-world data: A nationwide cohort study. Frontiers in Medicine 2023; 9 doi: 10.3389/fmed.2022.1076356
|
| 56 |
Md. Alimur Reza, Uttom Kumar Bhowmik, Sabrina Akter Tushi, Nayan Ghosh, Nithon Chandra Sahana, Md. Ashraful Islam, Nafisa Ahamed, Arifa Akram. Pharmacokinetic Comparison and Bioequivalence Evaluation of Two 20-mg Vonoprazan Fumarate Tablets in Bangladeshi Healthy Male Subjects. Journal of Biosciences and Medicines 2024; 12(08) doi: 10.4236/jbm.2024.128018
|
| 57 |
Kai-Juan Cao, Long Fu, Yu-Chen Sun, Jian Meng, Qin Huang, De-Cheng Deng, Hai-Tang Hu, Zhi-Hui Han, Gang Guo, Xue Zhou, Xiao-Yan Chen. CYP3A-Mediated Metabolism of Zastaprazan in Humans and Associated Drug–Drug Interactions. Pharmaceutics 2026; 18(6) doi: 10.3390/pharmaceutics18060718
|
| 58 |
Young-Min Han, Jong-Min Park, Song Her, Min Sun Kim, Yong Jin Park, Ki Baik Hahm. Revaprazan prevented indomethacin-induced intestinal damages by enhancing tight junction related mechanisms. Biochemical Pharmacology 2020; 182 doi: 10.1016/j.bcp.2020.114290
|
| 59 |
Ahmed Al-Marhabi, Ahmed Hashem, Bader Faiyaz Zuberi, Charles Onyekwere, Imran Lodhi, Mohamed Mounir, Saad Alkhowaiter, Sameer Al Awadhi, Vasudevan G. Naidoo, Yasser Hamada. The views of African and Middle Eastern Gastroenterologists on the management of mild-to-moderate, non-erosive gastro-esophageal reflux disease (GERD). Expert Review of Gastroenterology & Hepatology 2022; 16(3) doi: 10.1080/17474124.2022.2043744
|
| 60 |
Dharma Ayer, Dia Shah, Steven Sica, Kate Kennelly, Micheal Tadros, Jessica Farrell. GI Diseases Associated with Rheumatological and Vasculitic Conditions. Clinical Gastroenterology 2025; doi: 10.1007/978-3-032-07868-1_21
|